Amneal Pharmaceuticals (NYSE:AMRX) updated its FY 2019 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $0.52-0.62 for the period, compared to the Thomson Reuters consensus estimate of $0.61. Amneal Pharmaceuticals also updated its FY19 guidance to $0.52-0.62 EPS.
Several analysts recently commented on the company. ValuEngine raised Amneal Pharmaceuticals from a strong sell rating to a sell rating in a research note on Tuesday, May 7th. Raymond James downgraded Amneal Pharmaceuticals from a strong-buy rating to an outperform rating and dropped their price objective for the stock from $13.00 to $8.50 in a research note on Wednesday, July 10th. SunTrust Banks reaffirmed a buy rating and set a $5.00 price objective on shares of Amneal Pharmaceuticals in a research note on Tuesday. Piper Jaffray Companies raised Amneal Pharmaceuticals from a neutral rating to an overweight rating and set a $11.00 price objective on the stock in a research note on Monday, July 8th. Finally, Leerink Swann raised Amneal Pharmaceuticals from a market perform rating to an outperform rating in a research note on Monday, July 22nd. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of Hold and an average price target of $12.13.
AMRX stock opened at $2.91 on Thursday. The business’s 50-day moving average price is $4.94. The company has a market cap of $902.04 million, a PE ratio of 3.06, a PEG ratio of 0.30 and a beta of 1.41. The company has a debt-to-equity ratio of 3.44, a quick ratio of 1.37 and a current ratio of 2.11. Amneal Pharmaceuticals has a 1 year low of $2.78 and a 1 year high of $24.48.
Amneal Pharmaceuticals (NYSE:AMRX) last released its earnings results on Monday, August 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.14 by ($0.05). The firm had revenue of $404.60 million for the quarter, compared to the consensus estimate of $420.12 million. Amneal Pharmaceuticals had a positive return on equity of 27.22% and a negative net margin of 3.65%. Amneal Pharmaceuticals’s revenue for the quarter was down 12.5% on a year-over-year basis. During the same quarter last year, the company posted $0.24 EPS. On average, equities analysts expect that Amneal Pharmaceuticals will post 0.55 earnings per share for the current year.
In related news, major shareholder International Ltd Fosun acquired 1,642,300 shares of the business’s stock in a transaction on Monday, August 5th. The stock was purchased at an average cost of $3.04 per share, for a total transaction of $4,992,592.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Pradeep Bhadauria acquired 7,000 shares of the business’s stock in a transaction on Wednesday, May 15th. The shares were bought at an average price of $8.48 per share, with a total value of $59,360.00. The disclosure for this purchase can be found here. Insiders bought a total of 1,749,966 shares of company stock valued at $5,572,557 in the last 90 days. 26.34% of the stock is owned by corporate insiders.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.